Background/Aims: The anatomical complexity of the head and neck region and the lack of sufficiently specific and sensitive biomarkers often lead to the diagnosis of head and neck squamous cell carcinoma (HNSCC) at advanced stages. To identify novel biomarkers for early diagnosis of primary HNSCC through a minimally invasive method, we investigated circulating long noncoding RNA (lncRNA) levels in plasma of HNSCC patients. Methods: The global lncRNA expression profiles of HNSCC patients were measured using microarray and next-generation RNA-sequencing (RNA-seq) data from both circulating and tissue samples. The diagnosis prediction model based on the lncRNA signatures and clinical features was evaluated by multi-stage validation and risk score analysis. Results: The data showed that 432 lncRNA transcripts were differentially expressed by fold changes of >4 in circulating samples and 333 in tissues samples, respectively. Only 12 lncRNAs consistently emerged in these two kinds of samples. After the risk score analysis including a multistage validation, we identified three lncRNAs, namely, HOXA11-AS, LINC00964 and MALAT1, which were up-regulated in the plasma of HNSCC patients compared with those in healthy controls with merged areas under
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Introduction
Head and neck cancer (HNC) accounts for more than 630, 000 newly diagnosed cancer cases and over130, 000 cancer deaths annually [1, 2] . Head and neck squamous cell carcinoma (HNSCC), the most common malignant lesion in the head and neck region, originates in the oral cavity, oropharynx, hypopharynx, and larynx [3] . Although significant advances have been made in comprehensive therapeutics, the 5-year overall survival rate for patients with HNSCC has remained at approximately 50% in recent decades, mainly due to local recurrence and regional lymph node and distant metastasis [4, 5] . The anatomical complexity of the head and neck region and the lack of sufficiently specific and sensitive biomarkers often lead to the diagnosis of HNSCCs at advanced stages, which results in poor prognosis and survival rates [6] . Therefore, the identification of novel biomarkers for the early diagnosis of primary HNSCC will play an essential role in improving outcomes [4, 7] .
Long non-coding RNAs (lncRNAs) are a newly-identified class of RNAs that are more than 200 nucleotides in length without protein-coding functions [8] . Currently, highthroughput microarray profiles and RNA sequencing (RNA-seq) experiments have identified a large number of abnormally expressed lncRNAs in various cancers [9] [10] [11] [12] [13] [14] . The expression of lncRNAs is generally tissue-specific [15, 16] . Similar to proteins and microRNAs, lncRNAs have been reported as novel diagnostic and prognostic biomarkers in cancer not only in tumor tissues but also in blood [17] [18] [19] [20] [21] . In HNSCC, HOTAIR, UCA-1 and GAS5 are dysregulated and associated with poor prognosis [22] [23] [24] . Most recently, a study focused on plasma testing has shown that circulating lncRNAs RP11-160H22.5, XLOC_014172 and LOC149086 might be potential biomarkers for tumorigenesis and the latter two might be potential biomarkers for metastasis in hepatocellular carcinoma [25] . Similarly, circulating GAS5 levels may serve as a potential biomarker in predicting treatment response in HNSCC patients treated with chemoradiotherapy [26] .
To the best of our knowledge, although the biomarkers of HNSCC have been extensively investigated, studies focused on the diagnostic effects of circulating lncRNAs of this disease are rare. In the present study, we investigated the potential use of circulating lncRNAs in plasma as biomarkers of HNSCC. First, we identified aberrant expression of lncRNAs by analyzing the microarray and RNA-seq data from HNSCC patients and cancer-free control individuals (both circulating and tissue samples). Then, we employed reverse-transcription quantitative polymerase chain reaction (RT-qPCR) to confirm and validate the results in plasma from more HNSCC patients and cancer-free controls. Therefore, we generated a panel of differentially expressed lncRNAs in plasma that might serve as novel biomarkers for the diagnosis of HNSCC.
Materials and Methods

Study design
A total of 100 patients with HNSCC who were referred to the Department of Head and Neck Surgery at Nanjing Medical University Affiliated Cancer Hospital from 2012 to 2015 and 100 matched healthy individuals without any apparent disease were enrolled in the study. This study was performed in accordance with the Declaration of Helsinki (fifth revision, October 2000) of the World Medical Association and approved by the Ethical Committee of Nanjing Medical University Affiliated Cancer Hospital. Written informed consent was provided by all of the study participants. None of the patients had received any other treatment, such as radiotherapy or chemotherapy, prior to surgery. The diagnosis of HNSCC was confirmed by histopathological analysis of tumor tissue from the surgical resection specimen. Each tissue specimen was stored in liquid Table 1 .
Screening phase
The screening phase was divided into a training set and validation set. Twenty paired samples including samples from 20 patients with HNSCC and 20 healthy controls were used in the training set, while 100 samples from patients diagnosed with HNSCC and 100 samples from healthy controls served as the validation set.
Training set
All candidate lncRNAs were tested in a group of 20 plasma and tissue samples obtained from patients, as well as 20 plasma from healthy controls. The tissue samples included paired tumor tissues and adjacent normal tissues. All patients were pathologically diagnosed with HNSCC. The expression levels of candidate lncRNAs were analyzed in all samples, and the comparative 2 -ΔΔCt method was used to analyze the difference between patients and healthy controls.
Validation set
A case-control study was designed to validate the obvious difference of relative expression levels of the selected potential biomarkers in a cohort of 100 patients and 100 healthy controls.
RNA extraction
Total RNA was extracted from 50 mg tissue and 300 μL plasma via TRIzol reagent according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). Total RNA from each sample was quantified using NanoDrop ND-1000 (Thermo Fisher Scientific Inc., Waltham, MAc).
LncRNA microarray and data analysis RNA extracted from plasma samples from three patients diagnosed with HNSCC and three healthy controls, regarded as circulating samples, was selected for lncRNA microarray analysis using the Agilent (California, USA) microarray platform. Sample preparation and microarray hybridization were performed by CapitalBio Corporation (Beijing, China) according to the manufacturer's standard protocols as previously described [27] . Briefly, cDNA labeled with a fluorescent dye (Cy5 and Cy3-dCTP) was synthesized and hybridized to the Agilent human lncRNA+mRNA Array V4.0 (Agilent, Santa Clara, CA, United States). The data was analyzed for summarization, normalization and quality control by using the Agilent GeneSpring software V13.0 (Agilent Technologies, Inc). The data were log2 transformed and median centered by genes using the Adjust Data function of CLUSTER 3.0 software (University of Tokyo, Human Genome Center, Tokyo, Japan) and further analyzed with hierarchical clustering with average linkage. Tree visualization were performed by Java TreeView (Stanford University School of Medicine). Illumina HiSeq 2500 sequencing and data analysis RNA extracted from three HNSCC patients after surgery including paired tumor tissues and adjacent normal tissues, regarded as tissue samples, was subjected to RNA-seq analysis on the Illumina Hiseq 2500 platform (Illumina, USA) by CapitalBio Corporation according to the manufacturer's instructions described previously [28] . In brief, sequencing libraries were generated using the NEBNext® UltraTM Directional RNA Library Prep Kit for Illumina® (NEB, USA). The libraries were sequenced using high-throughput 125-bp paired-end mode by the Illumina Hiseq 2500 device. For the data analysis, base calls were performed using bcl2fastq2 (v2.20.0). Reads were filtered using NGSQC-toolkit (v2.3.3), and aligned to the genome using the split read aligner TopHat (v2.0.13) with the mismatches set at 2 and with the default parameters. The software package limma (v.10) was used to calculate the fold-change of transcripts and to screen all differentially expressed genes. Heatmap and cluster analyses were applied to the expression data set.
RT-qPCR
RT-qPCR was used to validate the data from the microarray and RNA-seq results. Total RNA from tissue and plasma samples was reverse transcribed using the reverse transcription kit (Takara, Tokyo, Japan). RTqPCR was then performed using an ABI Prism 7900HT system (Applied Biosystems, CA, USA).
Risk score analysis
Risk score analysis was performed to evaluate the associations between tissue and plasma lncRNA expression levels as previously described [25] . The upper 95% reference interval of each lncRNA in the control group was set as the threshold to code the expression level of the corresponding lncRNA for each sample as 0 and 1 in the training set. A risk score function (RSF) to predict the HNSCC group was defined according to a linear combination of the expression level for each lncRNA. For example, the RSF for sample i using information from three lncRNAs was: rsfi=∑3j-1Wj.sij, where, sij is the risk score for lncRNA j in sample i, and Wj is the weight of the risk score of lncRNA j. The risk score of three lncRNAs was calculated using the weight of the regression coefficient that was derived from the univariate logistic regression analysis of each lncRNA. Samples were ranked according to their RSF and then divided into a high-risk group, representing the HNSCC patients, and a low-risk group, representing the predicted control individuals. Frequency tables and receiver operating characteristic (ROC) curves were then used to evaluate the diagnostic effects of the profiling, find the appropriate cut-off point and validate the procedure and cutoffs in the next validation set.
Statistical analysis
Data are presented as the mean (SEM). Student's t-test and chi-square tests of variance were used to evaluate clinicopathological characteristics. The paired and unpaired student's t-test were used to compare significant differences in tissue and plasma lncRNA expression between patients and controls. Analysis of area under the ROC curve (AUC) was used to estimate the effectiveness of lncRNAs for prediction. Statistical analysis was performed using SPSS 22.0 software and GraphPad Prism 6.0. In all cases, p<0.05 was considered statistically significant. All p values were two-sided.
Results
High-throughput microarray and RNA-seq detection of circulating and tissue lncRNAs
The Agilent microarray and the Illumina HiSeq 2500 platform was employed to detect the lncRNAs derived from circulating and tissue samples. We randomly chose plasma samples obtained from three HNSCC patients before operation and from three healthy controls. The tissue samples included three matched primary HNSCC tissues and adjacent nontumor mucous membrane tissues. As presented in Fig. 1A-1D , aberrant expression of lncRNAs was detected in both circulating and tissue samples. To screen the candidate biomarkers for predicting HNSCC, we filtered the differentially expressed lncRNAs with the following parameters: i, lncRNAs with > 80% expression; ii, lncRNAs with fold changes > 4; and iii, lncRNAs increased in both circulating and tissue samples. As shown in Fig. 1E increased in tissue samples (tumor tissues). Only 12 lncRNAs were consistent with all the parameters mentioned above and were was further validated in the subsequent screening phase.
Validation of significantly dysregulated lncRNAs in plasma by RT-qPCR
To verify the microarray data in plasma, we validated the expression level of lncRNAs by RT-qPCR in plasma from 20 cancer patients and 20 cancer-free controls. No significant differences were detected in the distribution of age or sex between the cancer patients and cancer-free controls. The results showed that among the 12 candidate lncRNAs, six lncRNAs were significantly different in circulating samples. (Fig. 2) .
Next, the 6 candidate lncRNAs were confirmed in 20 tissue samples, including paired tumor and adjacent normal tissues, and 20 circulating samples from HNSCC patients and cancer-free patients. The 20 paired samples from the same patients are described in the previous paragraph. Only three lncRNAs were confirmed to be increased in both HNSCC patient plasma samples and tumor tissues (Fig. 3) .
Finally, we validated the 3 aberrantly expressed lncRNAs in samples from another 100 patients with HNSCC and 100 cancer-free controls. As presented in Fig. 4 , 3 out of 6 lncRNAs including HOXA11-AS, LINC00964 and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) were confirmed to be significant. 
Risk score analysis
Further experiments were conducted to explore the accuracy and specificity of these 3 lncRNAs as potential HNSCC biomarkers. Throughout the multiphase testing and analysis, a profile of three lncRNAs might be considered a potential signature for the diagnosis of HNSCC.
Risk score analysis was applied to evaluate the diagnostic value of the three lncRNAs. First, we divided the control group and case group in the training set according to the upper 95% credibility interval (95% CI) in the control group. The risk score was calculated based on the results of logistic regression analysis. All plasma samples were then divided into a high-risk group, indicating the possible HNSCC patients, and a low-risk group, representing the predicted controls. We defined the cutoff value as the maximal value of sensitivity + specificity. The positive predictive value (PPV) and negative predictive value (NPV) were calculated as 70% and 80% in the training set, respectively. We further applied the same value to calculate the risk score of samples in the validation sets, and, the PPV and NPV were 88% and 81%, respectively (Table 2) .
ROC curve analysis was used to evaluate the value of lncRNAs for predicting HNSCC. The AUCs of the three validated lncRNA were 0.773, 0.387 and 0.918, respectively, while the combination of the three lncRNAs displayed a moderate ability of discriminating between HNSCC patients and controls with an AUC of 0.925 (Fig. 5A) .
Next, ROC curve analysis was used to evaluate the value of lncRNAs for predicting HNSCC in the validation set. The AUCs of the three validated lncRNAs were 0.659, 0.687 and 0.718, respectively, while the combination of the three factors displayed a moderate ability of discriminating between HNSCC patients and controls with an AUC of 0.839 (Fig. 5B) . 
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Discussion
Although surprising advances have been made in cancer research and therapy, the survival of patients with HNSCC has not significantly improved in the last few decades [4, 5, 29] . There remains to date a lack of effective tumor-specific biomarkers for the early detection and prognostic prediction of HNSCC. Therefore, developing new, highly sensitive and specific biomarkers for the diagnosis of HNSCC is urgently needed to improve patient outcomes. Previously published studies on biomarkers in HNSCC have mainly focused on proteins and microRNAs. Epidermal growth factor receptor (EGFR), for instance, is associated with poor prognosis in HNSCC and can serve as a predictive biomarker for therapy response [30] [31] [32] . MiR-21 expression in the tumor stroma has a negative prognostic value in oral squamous cell carcinoma [33] . Low levels of both miR-205 and let-7d expression in HNSCC tumors are significantly associated with poor survival [34] .
Recently, lncRNAs have emerged as new regulators of cancer progression [14, 35] . MALAT1 is overexpressed and has been 
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Cellular Physiology and Biochemistry used as a new prognostic factor of survival in multiple cancers [36, 37] . MALAT1 may be a promising therapeutic target for suppressing cancer progression and drug resistance [38] [39] [40] . Low expression levels of both miR-26a and MEG3 are an independent prognostic factor for poor clinical outcomes in tongue squamous cell carcinoma (TSCC) patients [41] . LINC00152 derived from the Gene Expression Omnibus (GEO) database might serve as a potential biomarker for the early detection and prognostic prediction of TSCC [42] . A three-lncRNA panel (KTN1-AS1, LINC00460 and RP5-894A10.6) derived from the Atlas of Noncoding RNA in Cancer (TANRIC) database might be a novel biomarker for the accurate prognostic prediction of patients with HNSCC [43] . Circulating lncRNAs in peripheral blood can also be excellent diagnostic candidate biomarkers because of their stability in circulating and ability to be detected by minimally invasive methods in many cancers, including HNSCC [44] [45] [46] [47] .
To the best of our knowledge, although studies on the effects of lncRNAs on HNSCC are still ongoing, the global profiling of dysregulated lncRNAs in the plasma of HNSCC patients has never been explored utilizing both microarray profiling and next-generation sequencing. This is the first study assessing universal circulating lncRNAs for HNSCC diagnosis according to microarray and RNA-seq data obtained from both blood and tissues. In this study, regardless of the various tumor sites, we attempted to discover universal circulating lncRNA biomarkers of HNSCC.
Using the microarray and RNA-seq method, we could quantify the dysregulated expression levels of HNSCC-associated lncRNAs derived from both plasma and tissue samples. The data showed that 432 lncRNA transcripts were significantly differentially expressed by fold changes of > 4 in circulating samples and 333 in tissues samples, respectively. Only 12 lncRNAs consistently emerged in these two kinds of samples.
Then, utilizing risk score analysis involving a multistage validation, we evaluated the association between the lncRNA expression levels in plasma samples and the clinical features of HNSCC patients including age, sex, histologic grade, TNM stage, lymph node and distant metastasis. At this stage, we screened and discovered three novel candidate circulating lncRNAs, namely, HOXA11-AS, LINC00964 and MALAT1, which act as biomarkers in the early diagnosis of primary HNSCC. We selected these three candidate lncRNAs because they have not only been demonstrated to be significantly dysregulated in the plasma of HNSCC patients, but also been found to be stable in circulation when subjected to harsh conditions. The optimal cutoff values from ROC curve analyses indicated that the combined detection of these three biomarkers could discriminate HNSCC patients from healthy controls with a relatively high sensitivity (88%) and specificity (81%) and was more accurate than the individual detection of each biomarker. Furthermore, the ROC analysis showed that the combination of lncRNAs HOXA11-AS, LINC00964 and MALAT1 is suitable for the early diagnosis of HNSCC with merged AUCs in the training and validation sets of 0.925 and 0.839, respectively. From the ROC analysis, we found a remarkable difference in LINC00964 levels between the training set and validation set. Since the samples for the training set were chosen at random, this might have resulted in a poor ability to distinguish HNSCC patients from controls; however, the predictive ability can improve with an increase in the number of samples. Thus, the results might be more reliable with larger sample sizes.
HNCs encompass malignancies originating from multiple anatomical sites. Despite the anatomical diversity of the head and neck region, more than 90% of HNC cases are classified as HNSCC. The clinical management of HNSCC involves several challenges including the early detection of primary tumors.
HNSCC represents a genetically heterogeneous group of tumors in which the molecular characteristics and clinical outcomes vary widely. In this study, we focused on novel potential biomarkers related to HNSCC. For example, one of the most well-studied biomarkers of HNSCC is EGFR, which is commonly overexpressed in HNSCC and is a negative prognostic factor associated with poor local control and survival. Despite significant differences at the molecular level among certain HNSCC subtypes, we attempted to discover circulating lncRNA biomarkers for HNSCC in general.
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In this study, we performed simultaneous analysis of tissue and plasma samples, which is important for extracting some information on common variations from data sets. However, the results need to be sufficiently validated in the future for a comprehensive understanding of molecular deregulations in HNSCC cells in vitro and in vivo.
Conclusion
In conclusion, in this study, we identified three lncRNAs, namely, HOXA11-AS, LINC00964 and MALAT1, as potential biomarkers of tumorigenesis. However, this is only a preliminary study, and is limited by a small sample size. A deeper understanding of the potential function of the three lncRNAs in the regulation of HNSCC pathogenesis is necessary for us in the future.
Abbreviations
HNSCC (head and neck squamous cell carcinoma); lncRNAs (long noncoding RNAs); RTqPCR (reverse transcription quantitative polymerase chain reaction); ROC (curve, receiver operating characteristic curve); AUC (area under the curve); RSF (risk score function).
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
